en
Scientific article
Review
French

Anticoagulants oraux directs dans le traitement des événements thrombo­emboliques veineux liés au cancer

Published inRevue médicale suisse, vol. 15, no. 674, p. 2232-2235
Publication date2019
Abstract

The use of direct oral anticoagulants (DOACs) has been largely -implemented in the management of venous thromboembolic disease in non-cancer patients. In cancer-associated thrombosis, low molecular weight heparins (LMWHs) and especially dalteparin have long been the reference standard therapy. Following the publication of two randomised trials comparing edoxaban and rivaroxaban to -dalteparin, DOACs now represent an alternative with an interesting efficacy and safety profile. Moreover, they offer the comfort of an oral administration and a lower cost. In patients with gastrointestinal or genitourinary cancers however, a higher bleeding risk has been shown with DOACs. LMWHs thus remain the treatment of choice in this group of patients.

Citation (ISO format)
STEBLER-FONTAINE, Laura et al. Anticoagulants oraux directs dans le traitement des événements thrombo­emboliques veineux liés au cancer. In: Revue médicale suisse, 2019, vol. 15, n° 674, p. 2232–2235.
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1660-9379
249views
0downloads

Technical informations

Creation12/12/2019 4:38:00 PM
First validation12/12/2019 4:38:00 PM
Update time03/15/2023 10:02:32 PM
Status update03/15/2023 10:02:31 PM
Last indexation01/17/2024 9:59:11 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack